Canopy Growth
CGCCanopy Growth Corporation (TSX: CGC, NASDAQ: CGC) is a Canada-based cannabis and consumer packaged goods company. Its primary business is the production, distribution, and sale of a diverse portfolio of cannabis and hemp-based products for both the medical and recreational markets. The company operates through a range of brands that target distinct consumer segments, offering dried flower, oils, softgel capsules, and infused beverages. Within the biotech sector, Canopy Growth has engaged in research and development activities focused on the therapeutic applications of cannabinoids. The company has conducted and supported clinical research in areas including chronic pain, insomnia, and anxiety. Its medical division provides products to patients in several countries where medical cannabis is legally regulated. As a publicly traded entity, Canopy Growth’s strategic direction has included partnerships and acquisitions aimed at expanding its product development capabilities and geographic footprint. The company maintains production facilities in Canada and has established supply agreements for international medical cannabis markets. Its operations are subject to the regulatory frameworks of the jurisdictions in which it operates.
CGC · Stock Price
Historical price data
About
Canopy Growth Corporation (TSX: CGC, NASDAQ: CGC) is a Canada-based cannabis and consumer packaged goods company. Its primary business is the production, distribution, and sale of a diverse portfolio of cannabis and hemp-based products for both the medical and recreational markets. The company operates through a range of brands that target distinct consumer segments, offering dried flower, oils, softgel capsules, and infused beverages. Within the biotech sector, Canopy Growth has engaged in research and development activities focused on the therapeutic applications of cannabinoids. The company has conducted and supported clinical research in areas including chronic pain, insomnia, and anxiety. Its medical division provides products to patients in several countries where medical cannabis is legally regulated. As a publicly traded entity, Canopy Growth’s strategic direction has included partnerships and acquisitions aimed at expanding its product development capabilities and geographic footprint. The company maintains production facilities in Canada and has established supply agreements for international medical cannabis markets. Its operations are subject to the regulatory frameworks of the jurisdictions in which it operates.